152 related articles for article (PubMed ID: 11905670)
1. Mode of action of farnesyltransferase inhibitors.
Prendergast GC
Lancet Oncol; 2000 Oct; 1():73. PubMed ID: 11905670
[No Abstract] [Full Text] [Related]
2. Farnesyltransferase inhibitors.
Adjei AA
Cancer Chemother Biol Response Modif; 2001; 19():149-64. PubMed ID: 11686012
[No Abstract] [Full Text] [Related]
3. Farnesyltransferase inhibitors.
Adjei AA
Cancer Chemother Biol Response Modif; 2002; 20():151-67. PubMed ID: 12703204
[No Abstract] [Full Text] [Related]
4. [Inhibitors of farnesyltransferase: a new approach for development of potential cancer drugs].
Schlitzer M
Pharm Unserer Zeit; 1998 Nov; 27(6):278-88. PubMed ID: 9894422
[No Abstract] [Full Text] [Related]
5. [CAAX peptidomimetics: their farnesyltransferase inhibition activity and antitumor effect].
Ohkanda J
Seikagaku; 2002 Jan; 74(1):46-50. PubMed ID: 11889772
[No Abstract] [Full Text] [Related]
6. The farnesyltransferase inhibitor L-744,832 inhibits the growth of astrocytomas through a combination of antiproliferative, antiangiogenic, and proapoptotic activities.
Feldkamp MM; Lau N; Guha A
Ann N Y Acad Sci; 1999; 886():257-60. PubMed ID: 10667233
[No Abstract] [Full Text] [Related]
7. Farnesyltransferase inhibitors.
Adjei AA
Cancer Chemother Biol Response Modif; 2003; 21():127-44. PubMed ID: 15338743
[No Abstract] [Full Text] [Related]
8. RhoB and the cellular response to farnesyltransferase inhibitors: the search for clues to cell death mechanisms.
Bernhard EJ
Cancer Biol Ther; 2003; 2(3):281-2. PubMed ID: 12878866
[No Abstract] [Full Text] [Related]
9. Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides.
Mitsch A; Wissner P; Silber K; Haebel P; Sattler I; Klebe G; Schlitzer M
Bioorg Med Chem; 2004 Sep; 12(17):4585-600. PubMed ID: 15358286
[TBL] [Abstract][Full Text] [Related]
10. Isolation of farnesyltransferase inhibitors from herbal medicines.
Kwon BM; Lee SH; Kim MJ; Kim HK; Kim HM
Ann N Y Acad Sci; 1999; 886():261-4. PubMed ID: 10667234
[No Abstract] [Full Text] [Related]
11. CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents.
Omer CA; Kohl NE
Trends Pharmacol Sci; 1997 Nov; 18(11):437-44. PubMed ID: 9426472
[TBL] [Abstract][Full Text] [Related]
12. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
[TBL] [Abstract][Full Text] [Related]
13. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
[TBL] [Abstract][Full Text] [Related]
14. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Schlitzer M; Böhm M; Sattler I
Bioorg Med Chem; 2002 Mar; 10(3):615-20. PubMed ID: 11814849
[TBL] [Abstract][Full Text] [Related]
15. RAS inhibitors: potential for cancer therapeutics.
Kloog Y; Cox AD
Mol Med Today; 2000 Oct; 6(10):398-402. PubMed ID: 11006529
[TBL] [Abstract][Full Text] [Related]
16. Opinion: Searching for the elusive targets of farnesyltransferase inhibitors.
Sebti SM; Der CJ
Nat Rev Cancer; 2003 Dec; 3(12):945-51. PubMed ID: 14737124
[No Abstract] [Full Text] [Related]
17. Synthesis and evaluation of homofarnesoyl-substituted CAAX-peptidomimetics as farnesyltransferase inhibitors and antiproliferative agents.
Schlitzer M; Sattler I; Dahse HM
Bioorg Med Chem; 1999 Sep; 7(9):2037-45. PubMed ID: 10530953
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
Brunner TB; Hahn SM; Gupta AK; Muschel RJ; McKenna WG; Bernhard EJ
Cancer Res; 2003 Sep; 63(18):5656-68. PubMed ID: 14522880
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects.
Prendergast GC
Curr Opin Cell Biol; 2000 Apr; 12(2):166-73. PubMed ID: 10712917
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics.
Koblan KS; Kohl NE; Omer CA; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A; Gibbs JB
Biochem Soc Trans; 1996 Aug; 24(3):688-92. PubMed ID: 8878827
[No Abstract] [Full Text] [Related]
[Next] [New Search]
